| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot knockout validation; mouse; fig 5c
| Mirzamohammadi F, Kozlova A, Papaioannou G, Paltrinieri E, Ayturk U, Kobayashi T. Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. Nat Commun. 2018;9:1352 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 5b
| Dong F, Chen M, Jiang L, Shen Z, Ma L, Han C, et al. PRMT5 Is Involved in Spermatogonial Stem Cells Maintenance by Regulating Plzf Expression via Modulation of Lysine Histone Modifications. Front Cell Dev Biol. 2021;9:673258 pubmed publisher |
- ChIP-Seq; mouse; loading ...; fig 6a
- western blot; mouse; 1:200; loading ...; fig s2e
- western blot; human; 1:200; fig s9g
| Brady N, Bagadion A, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12:3372 pubmed publisher |
- flow cytometry; human; loading ...; fig 4b
| Kuchen E, Becker N, Claudino N, Hofer T. Hidden long-range memories of growth and cycle speed correlate cell cycles in lineage trees. elife. 2020;9: pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 2a
| Liu P, Tee A, Milazzo G, Hannan K, Maag J, Mondal S, et al. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. Nat Commun. 2019;10:5026 pubmed publisher |
- western blot; human; 1:200; loading ...; fig 4e, 4h
| Menon V, Thomas R, Elgueta C, Horl M, Osborn T, Hallett P, et al. Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. Stem Cells. 2019;37:1293-1306 pubmed publisher |
- western blot; human; 1:500; loading ...; fig 2c
| Mooney M, Geerts D, Kort E, Bachmann A. Anti-tumor effect of sulfasalazine in neuroblastoma. Biochem Pharmacol. 2019;162:237-249 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 5b
| Otto T, Candido S, Pilarz M, Sicinska E, Bronson R, Bowden M, et al. Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit. Proc Natl Acad Sci U S A. 2017;114:10660-10665 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:500; fig s9a
| van Groningen T, Koster J, Valentijn L, Zwijnenburg D, Akogul N, Hasselt N, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49:1261-1266 pubmed publisher |
- western blot; human; 1:2000; loading ...; fig 1a
| Xue C, Yu D, Gherardi S, Koach J, Milazzo G, Gamble L, et al. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget. 2016;7:54937-54951 pubmed publisher |
- western blot; human; loading ...; fig s2b
| Powers J, Tsanov K, Pearson D, Roels F, Spina C, EBRIGHT R, et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016;535:246-51 pubmed publisher |
- ChIP-Seq; human; fig 5
- western blot; human; 1:1000; fig s3
| Duffy D, Krstic A, Halasz M, Schwarzl T, Fey D, Iljin K, et al. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget. 2015;6:43182-201 pubmed publisher |
- western blot; human; fig 1
| Xiao D, Ren P, Su H, Yue M, Xiu R, Hu Y, et al. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget. 2015;6:40655-66 pubmed publisher |
- western blot; mouse; fig 5a
- western blot; human; fig s1c
| Petroni M, Sardina F, Heil C, Sahún Roncero M, Colicchia V, Veschi V, et al. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. Cell Death Differ. 2016;23:197-206 pubmed publisher |
- chromatin immunoprecipitation; human; fig 3A
- immunoprecipitation; human; fig 1A
- western blot; human; fig 1A
| Amente S, Milazzo G, Sorrentino M, Ambrosio S, Di Palo G, Lania L, et al. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma. Oncotarget. 2015;6:14572-83 pubmed |
- western blot; human; 1:500; fig s1
| Chen L, Rousseau R, Middleton S, Nichols G, Newell D, Lunec J, et al. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015;6:10207-21 pubmed |
- chromatin immunoprecipitation; human
- western blot; human; fig 6
| Chayka O, D Acunto C, Middleton O, Arab M, Sala A. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells. J Biol Chem. 2015;290:2198-212 pubmed publisher |
- immunoprecipitation; human; fig 8
| Gustafson W, Meyerowitz J, Nekritz E, Chen J, Benes C, Charron E, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014;26:414-427 pubmed publisher |
- chromatin immunoprecipitation; human
- immunoprecipitation; human
| Corvetta D, Chayka O, Gherardi S, D Acunto C, Cantilena S, Valli E, et al. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem. 2013;288:8332-41 pubmed publisher |
| De Rosa P, Severi F, Zadran S, Russo M, Aloisi S, Rigamonti A, et al. MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. Int J Mol Sci. 2023;24: pubmed publisher |
| Alborzinia H, Flórez A, Kreth S, Brückner L, Yildiz U, Gartlgruber M, et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer. 2022;3:471-485 pubmed publisher |
| Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, et al. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020;11:913 pubmed publisher |
| Huang M, Tailor J, Zhen Q, Gillmor A, Miller M, Weishaupt H, et al. Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell. 2019;: pubmed publisher |
| Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Mol Cancer. 2019;18:11 pubmed publisher |
| Hald Ø, Olsen L, Gallo Oller G, Elfman L, Løkke C, Kogner P, et al. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene. 2019;38:2800-2813 pubmed publisher |
| Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood K, et al. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer. 2019;144:3146-3159 pubmed publisher |
| Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe Chiweshe A, Connolly E, et al. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018;37:5451-5465 pubmed publisher |
| Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, et al. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. Oncotarget. 2018;9:20323-20338 pubmed publisher |
| O Brien E, Selfe J, Martins A, Walters Z, Shipley J. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. BMC Cancer. 2018;18:217 pubmed publisher |
| Ferrucci F, Ciaccio R, Monticelli S, Pigini P, Di Giacomo S, Purgato S, et al. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. Biochim Biophys Acta Gene Regul Mech. 2018;1861:235-245 pubmed publisher |
| Chen L, Alexe G, Dharia N, Ross L, Iniguez A, Conway A, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018;128:446-462 pubmed publisher |
| Bosse K, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, et al. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017;32:295-309.e12 pubmed publisher |
| Dyberg C, Fransson S, Andonova T, Sveinbjörnsson B, Lännerholm Palm J, Olsen T, et al. Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2017;114:E6603-E6612 pubmed publisher |
| King B, Boccalatte F, Moran Crusio K, Wolf E, Wang J, Kayembe C, et al. The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol. 2016;17:1312-1321 pubmed publisher |
| Eberhardt A, Hansen J, Koster J, Lotta L, Wang S, Livingstone E, et al. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget. 2016;7:63629-63639 pubmed publisher |
| Murakami Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, et al. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep. 2016;6:31615 pubmed publisher |
| Duffy D, Krstic A, Schwarzl T, Halasz M, Iljin K, Fey D, et al. Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget. 2016;7:60310-60331 pubmed publisher |
| Mandriota S, Valentijn L, Lesne L, Betts D, Marino D, Boudal Khoshbeen M, et al. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 2015;6:18558-76 pubmed |
| Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, et al. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Lett. 2015;363:37-45 pubmed publisher |
| Ambrosio S, Amente S, Napolitano G, Di Palo G, Lania L, Majello B. MYC impairs resolution of site-specific DNA double-strand breaks repair. Mutat Res. 2015;774:6-13 pubmed publisher |
| Izumi H, Kaneko Y. Trim32 facilitates degradation of MYCN on spindle poles and induces asymmetric cell division in human neuroblastoma cells. Cancer Res. 2014;74:5620-30 pubmed publisher |
| Murakami Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris J, Ichikawa H, et al. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle. 2014;13:1115-31 pubmed publisher |
| Lodrini M, Oehme I, Schroeder C, Milde T, Schier M, Kopp Schneider A, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013;41:6018-33 pubmed publisher |
| Watters K, Bryan K, Foley N, Meehan M, Stallings R. Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells. BMC Cancer. 2013;13:184 pubmed publisher |
| Valli E, Trazzi S, Fuchs C, Erriquez D, Bartesaghi R, Perini G, et al. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim Biophys Acta. 2012;1819:1173-85 pubmed publisher |
| Tivnan A, Orr W, Gubala V, Nooney R, Williams D, McDonagh C, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129 pubmed publisher |
| Varlakhanova N, Cotterman R, Bradnam K, Korf I, Knoepfler P. Myc and Miz-1 have coordinate genomic functions including targeting Hox genes in human embryonic stem cells. Epigenetics Chromatin. 2011;4:20 pubmed publisher |
| Murphy D, Buckley P, Bryan K, Watters K, Koster J, van Sluis P, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50:403-11 pubmed publisher |
| Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, et al. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011;71:404-12 pubmed publisher |
| Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res. 2010;70:3791-802 pubmed publisher |
| Veas Perez de Tudela M, Delgado Esteban M, Cuende J, Bolanos J, Almeida A. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J Neurochem. 2010;113:819-25 pubmed publisher |
| Murphy D, Buckley P, Bryan K, Das S, Alcock L, Foley N, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS ONE. 2009;4:e8154 pubmed publisher |
| Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10:R64 pubmed publisher |
| Westermann F, Muth D, Benner A, Bauer T, Henrich K, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008;9:R150 pubmed publisher |
